Source facts
FDA issued an approval letter for BYSANTI on 2026-02-24. The source metadata identifies NDA 220358 as an original application. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
BYSANTI — FDA Approval Letter (NDA 220358)
Issued to VANDA PHARMS INC. Application is approved as submitted.
Issued
February 24, 2026Application
NDA 505b1 • 220358
Product
BYSANTI
Company
VANDA PHARMS INC
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for BYSANTI?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 220358.
- 3Submission: original application.
- 4Sponsor: VANDA PHARMS INC.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the BYSANTI approval letter
Is BYSANTI FDA approved?
This letter documents an FDA approval action: FDA approved NDA 220358 for BYSANTI, sponsored by VANDA PHARMS INC, on February 24, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 220358?
NDA 220358 is the application under which FDA issued this approval letter for BYSANTI to VANDA PHARMS INC. The letter is dated February 24, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.